| HOME >> BIOLOGY >> TECHNOLOGY |
-------------------------------------------------------------------------
EXPENSES
Research and development 2,185,756 2,667,360
General and administrative 512,560 593,819
Stock-based compensation 142,274 146,439
Amortization of intellectual property 110,537 110,537
Interest on long-term debt 30,528 2,653
-------------------------------------------------------------------------
2,981,655 3,520,808
-------------------------------------------------------------------------
Interest income 101,060 183,321
-------------------------------------------------------------------------
Net and comprehensive loss for the period (2,586,310) (1,671,251)
Deficit, beginning of period (33,348,130) (23,714,085)
-------------------------------------------------------------------------
Deficit, end of period (35,934,440) (25,385,336)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net and comprehensive loss per common share
Basic and fully diluted $(0.05) $(0.03)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average number of common
shares outstanding
Basic and fully diluted 55,518,769 55,431,359
-------------------------------------------------------------------------
-------------------------------------------------------------------
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |